Nestlé Secures Full Ownership of Aimmune to Lead Food Allergy Market
Nestlé strengthens its medical nutrition division by acquiring full control of Aimmune Therapeutics in a multi-billion dollar deal.
By Foodie Pundit Newsroom - Published - Updated - Section: Deals Value
Key points
- Nestlé S.A. acquires the remaining equity in Aimmune Therapeutics for approximately 2.6 billion dollars to bolster its medical nutrition business.
- The deal gives Nestlé full ownership of Palforzia, the first FDA-approved therapeutic treatment designed to mitigate severe peanut allergies.
- Major food conglomerates are increasingly investing in clinical technology to capture high-margin, science-backed health markets.
- The integration bridges the gap between pharmaceutical research and consumer food products, raising safety standards across the industry.
This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.
Sources and methodology
Reported from the public datasets below.
- Federal Reserve Economic Data (FRED) - Food services and drinking places series
- Bureau of Labor Statistics (BLS) - Consumer Price Index, food away from home
- U.S. Census Bureau - Monthly Retail Trade, food services
- Bureau of Labor Statistics (BLS) - Consumer Price Index, food away from home
- Federal Reserve Economic Data (FRED) - Food services and drinking places series
- U.S. Census Bureau - Monthly Retail Trade, food services
More from the Foodie Pundit Newsroom
- Loud Budgeting Reshapes Restaurant Social Norms and Spending Habits
- The Sweet Consolidation: How a Few Giants Captured the World's Dessert Aisle
- How Fine Dining Secrets and Viral Trends Are Transforming the Food Service Economy
- The Great Uncorking: How Your Bar Cart Became The New Craft Mecca
- General Mills Expands Profit Margins as Strategic Price Increases Outpace Input Costs